€543.60
0.55% today
Brüssel, Apr 01, 05:37 pm CET
ISIN
NL0010832176
Symbol
ARGX
Sector
Industry

arGEN-X Stock price

€543.60
-60.20 9.97% 1M
+51.20 10.40% 6M
-56.40 9.40% YTD
+177.50 48.48% 1Y
+253.30 87.25% 3Y
+423.60 353.00% 5Y
+534.53 5,893.38% 10Y
Brüssel, Closing price Tue, Apr 01 2025
+3.00 0.55%
ISIN
NL0010832176
Symbol
ARGX
Sector
Industry

Key metrics

Market capitalization €32.85b
Enterprise Value €29.62b
P/E (TTM) P/E ratio 42.05
EV/FCF (TTM) EV/FCF 1,182.99
EV/Sales (TTM) EV/Sales 14.63
P/S ratio (TTM) P/S ratio 16.22
P/B ratio (TTM) P/B ratio 6.19
Revenue growth (TTM) Revenue growth 78.50%
Revenue (TTM) Revenue €2.02b
EBIT (operating result TTM) EBIT €-70.26m
Free Cash Flow (TTM) Free Cash Flow €25.04m
EPS (TTM) EPS €12.86
P/E forward 49.67
P/S forward 9.85
EV/Sales forward 8.88
Show more

Is arGEN-X a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

arGEN-X Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a arGEN-X forecast:

29x Buy
88%
4x Hold
12%

Analyst Opinions

33 Analysts have issued a arGEN-X forecast:

Buy
88%
Hold
12%

Financial data from arGEN-X

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
2,025 2,025
78% 78%
100%
- Direct Costs 219 219
5% 5%
11%
1,806 1,806
95% 95%
89%
- Selling and Administrative Expenses 956 956
72% 72%
47%
- Research and Development Expense 903 903
30% 30%
45%
-54 -54
84% 84%
-3%
- Depreciation and Amortization 16 16
84% 84%
1%
EBIT (Operating Income) EBIT -70 -70
84% 84%
-3%
Net Profit 770 770
382% 382%
38%

In millions EUR.

Don't miss a Thing! We will send you all news about arGEN-X directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,599
Founded 2008
Website www.argen-x.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today